1.	Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Phase: Phase IV Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CICL670A2412-HMO-CTIL, NCT00452660
2.	Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Phase: Phase IV Type: Diagnostic, Supportive care Status: Active Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AAU01, NCT00673608
3.	Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study Phase: Phase IV Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670A2417, 2011-001077-13, NCT01326845
4.	Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670A2302, 2009-012418-38, NCT00940602
5.	Exjade-Early-Trial Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CICL670ADE06T, NCT01058369